share_log

Immuneering Announces FDA Clearance of IND Application for Phase 1/2a Clinical Trial of IMM-1-104 to Treat Advanced Solid Tumors With RAS Mutations

Immuneering Announces FDA Clearance of IND Application for Phase 1/2a Clinical Trial of IMM-1-104 to Treat Advanced Solid Tumors With RAS Mutations

免疫系统公司宣布FDA批准了IMM-1-104治疗RAS突变的晚期实体肿瘤的1/2a期临床试验的IND申请
Benzinga Real-time News ·  2022/09/30 06:52

Immuneering Announces FDA Clearance of IND Application for Phase 1/2a Clinical Trial of IMM-1-104 to Treat Advanced Solid Tumors with RAS Mutations

免疫系统公司宣布FDA批准了IMM-1-104治疗RAS突变的晚期实体肿瘤的1/2a期临床试验的IND申请

声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发